Did you know that a simple barcode scan could hold the key to revolutionizing productivity across industries? Imagine a world where medication administration, inventory management, and patient care ...

Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...

This year’s ASH saw a plethora of presentations on BCMA-targeting drugs, but analysts at Jefferies say Bluebird Bio’s CAR-T therapy bb2121 “is still leading the pack.” The action-packed conference saw ...

Researchers noted that despite the promising findings, more novel treatments are needed to overcome the disease’s resistance. Patients with penta-relapsed refractory multiple myeloma (RRMM) exhibited ...

The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for ...

Please provide your email address to receive an email when new articles are posted on . Long-term results from the KarMMa trial continued to yield frequent deep and durable responses with idecabtagene ...

Great targets are scarce, and so researchers across the biopharmaceutical industry tend to pile in when they come along. And when the biology is just right, such targets promise not just new ...

In a clinical trial of 7 patients, anti-BCMA only CAR-T cell treated patients with refractory lupus nephritis safely and effectively. Anti-B cell maturation antigen (BCMA)-targeting chimeric antigen ...

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its linvoseltamab drug candidate.